jective is to elucidate the effect of nitric oxide (NO)-renin-angiotensin system (RAS) interactions on renal hemodynamic function in uncomplicated, type 1 diabetes mellitus (DM). In 14 salt-replete, male healthy volunteers (C) and 9 male DM patients on euglycemia, glomerular filtration rate (GFR), renal blood flow (RBF), filtration fraction (FF), and sodium excretion (UNaV) were measured at baseline and during a 90-min infusion of 3.0 g·kg
Ϫ1

·min
Ϫ1 N G -nitro-Larginine-methyl-ester (L-NAME) after 3 days of pretreatment with either placebo (PL) or 50 mg losartan (LOS). Baseline GFR, RBF, and FF were higher in DM (P Ͻ 0.005). In the C group, PL ϩ L-NAME caused declines in GFR (101 Ϯ 3 to 90 Ϯ 3 ml·min ), and UNaV (158 Ϯ 12 to 82 Ϯ 18 mol/min) and an increase in FF (0.19 Ϯ 0.02 to 0.21 Ϯ 02; P Ͻ 0.001), which were not influenced by LOS pretreatment (P Ͼ 0.05 for LOS ϩ L-NAME-C vs. PL ϩ L-NAME-C). In DM, PL ϩ L-NAME resulted in exaggerated renal effects, with changes in GFR (128 Ϯ 3 to 104 Ϯ 3 ml·min ), UNaV (150 Ϯ 13 to 39 Ϯ 14 mol/min), and FF (0.22 Ϯ 0.03 to 0.26 Ϯ 0.02) that were significantly greater vs. PL ϩ L-NAME-C (P Ͻ 0.005). LOS pretreatment blunted GFR, RBF, FF, and UNaV responses to L-NAME in DM (P Ͻ 0.005 vs. PL ϩ L-NAME-DM), resulting in a response profile that was similar to PL ϩ L-NAME and LOS ϩ L-NAME in C (P Ͼ 0.05). Renal responses to L-NAME in uncomplicated, type 1 DM are exaggerated vs. C, consistent with an upregulation of NO bioactivity. LOS, without effects in C, prevents the accentuated actions of L-NAME in DM, thus indicating an augmented role for NO-RAS interactions in renal hemodynamic function in DM. type 1 diabetes mellitus; renal hemodynamic function; nitric oxide; renin-angiotensin system; L-NAME; losartan IN EXPERIMENTAL MODELS OF early diabetes mellitus (DM) and in type 1 DM patients, renal hemodynamic function is abnormal, with lowered renal vascular resistance (RVR), and elevated renal blood flow (RBF), glomerular filtration rate (GFR), filtration fraction (FF), and glomerular capillary pressure (P GC ; Refs. 7, 8, 12, 13, 20, 36, 39, 43, 45) . High P GC may be predictive of a higher risk for progressive nephropathy in human DM, and glomerular hyperfiltration is generally accepted as a surrogate marker for P GC in humans with DM (12, 45) .
Alterations in the renin-angiotensin system (RAS), cyclooxygenase-dependent prostanoids (PG), nitric oxide (NO), and tubuloglomerular feedback (TGF) have been implicated in the DM hyperperfusion/hyperfiltration state (7, 8, 11-14, 23-25, 27, 36, 39, 43, 45) . Based on the exaggerated renal hemodynamic responses to pharmacological RAS blockade, which also blunts elevations in GFR during clamped hyperglycemia, activation of the intrarenal RAS is a known determinant of hyperfiltration state in DM patients through efferent vasoconstriction (11, 12, 23, 27, 32, 36, 39, 43) . However, RAS inhibition only leads to a partial correction of high GFR in DM humans, suggesting a role for non-RAS factors such as NO (7, 8, 12, 13, 23, 27, 43, 45) .
In early experimental DM, inappropriately low afferent resistance is related to increased intrarenal NO generation (7, 8, 12, 13, 24, 25) . In human DM, enhanced NO production has been suggested by an elevated urinary 15 N nitrate excretion from radiolabeled L-arginine (37) and higher circulating and urinary levels of NO (14, 36) . We have also recently reported exaggerated declines in RBF and GFR and increases in FF in response to the NOS inhibitor N G -monomethyl-L-arginine (L-NMMA), consistent with the role of increased renal NO bioactivity (13) .
In addition to isolated effects of each neurohormonal system, control of renal hemodynamic function is ultimately the result of interactions between the vasodilator-natriuretic systems, such as NO, and vasoconstrictor, Na ϩ -retaining systems, such as the RAS. Since the effects of angiotensin II (ANG II) on renal hemodynamic function and Na ϩ excretion (UNaV) are markedly potentiated by NO-synthase inhibition (NOSI), it has been suggested that the results of NOSI reflect both the removal of baseline NO-dependent vasodilatory-natriuretic effects and the action of unopposed endogenous ANG II (1, 3, 4, 29, 41) . It is perhaps because of these ANG II-NO interactions that RAS blockade blunts the renal effects of NOSI in animals with marked activation of intrarenal RAS and sympathetic nervous system (4, 24, 29, 41) .
In healthy humans with RAS activation due to Na ϩ -restriction, however, the renal effects of L-NMMA are reduced rather than accentuated compared with the Na ϩ -replete state (2, 5), and AT 1 receptor blockade does not exert any effect on NOSI-induced renal changes in both Na ϩ -replete and chronically diuretic-treated non-DM humans (6, 16, 33, 38, 46) . Therefore, the degree of intrarenal RAS activation elicited by Na ϩ balance-dependent stimuli is insufficient to make the renal actions of NOSI become ANG II dependent.
Since the effects of RAS inhibition on renal responses to NOSI critically depend on the degree of intrarenal RAS activation (3, 4, 29, 41), these changes could become ANG II dependent when intrarenal RAS, irrespective of Na ϩ balance, is endogenously upregulated, as in experimental and human DM (12, 23-25, 27, 32, 39, 43, 45) . Whether or not NO-RAS interactions contribute to the regulation of renal hemodynamic function in humans with uncomplicated, type 1 DM has not, however, been clarified. Accordingly, our aim was to determine the extent to which the enhanced response to NOSI in DM (13, 24) is due to baseline increased NO bioactivity or, instead, due to the unopposed intrarenal RAS activation. Our hypothesis was that, in contrast with what is known in non-DM humans (6, 16, 33, 38, 46) , previous AT 1 blockade would prevent the accentuated responses to acute NOSI in DM patients, thus indicating an augmented role of NO-RAS interactions in the regulation of kidney function in DM. We therefore studied the renal hemodynamic and excretory effects of low-dose N G -nitro-L-arginine-methyl-ester (L-NAME) in Na ϩ -replete, healthy human volunteers (C) and in patients with uncomplicated type 1 DM after a short-term pretreatment with either placebo (PL) or losartan (LOS).
METHODS
Participants. Fourteen nonsmoker, male C volunteers and 9 male patients with uncomplicated type 1 DM, previously submitted to a baseline clinical examination and laboratory screening on their habitual Na ϩ intake (Table 1) , were included in the study after providing written informed consent according to the ethical protocols of our Institution. Inclusion criteria were no medication except insulin; no obesity; dyslipidemia; drug or alcohol abuse; heart, liver, kidney, or endocrine diseases or atherosclerosis based on history; clinical examination; laboratory screening; electrocardiogram; and heart, abdomen, and vascular ultrasound standard studies. All participants had 24-h urinary albumin excretion (UAE) Ͻ20 g/min and normal blood pressure (BP), with mean sitting systolic pressure (SAP) Ͻ130 mmHg and diastolic pressure (DAP) Ͻ80 mmHg, as measured on three separate visits (Table 1) Experimental design and procedures. Participants underwent in a randomized order two L-NAME infusion studies (33, 34, 38) , with a 2-wk washout period in between study days. For 7 days before each infusion, they were placed on a controlled daily diet, containing 230 Ϯ 10 mmol Na ϩ , 80 Ϯ 6 mmol K ϩ , and 2,450 Ϯ 70 Kcal (55% carbohydrates, 15% protein, and 30% lipids), and a fixed intake of antioxidants and preformed NO2 ϩ NO3 (NOx), based on its content in vegetables, fruit, and processed meats (36) . To avoid any confounding disturbance of PG production (12, 29, 38) , nonsteroidal antiinflammatory drugs were specifically forbidden along study. The adherence to diet was estimated at the baseline of each study based on written food record, UNaV, and urinary urea nitrogen (UUN) and NOx (UNOxV; Ref. 36). At 10:00 PM before each study, Li2CO3 8 mmol was administered for estimate of tubular Na ϩ reabsorption proximal to the macula densa (MD; Refs. 9, 20, [33] [34] [35] [36] .
Participants received in the 3 days before each study either PL or commercially available 50 mg LOS at 10:00 PM, thus preventing systemic and renal hemodynamic changes related to an acute AT1 blockade (18, 40) . Such doses of LOS counteract effectively in humans the BP and renal effects of exogenous ANG II (18) and prevent the low-dose L-NAME-induced BP increases even 10 -12 h after administration (33, 38) .
In each participant, after fasting overnight, on arrival to the laboratory (7:00 AM), two plastic indwelling catheters were placed at both arms, the left for infusions and the right for blood sampling, and kept patent with 1.0 ml/h 0.9% NaCl. Since a formal euglycemic clamp (11, 12, 32) was not feasible, to limit the impact of hyperglycemia in Values are means Ϯ SE. Demography, clinical data, and laboratory results on the baseline condition of habitual Na ϩ intake in 14 healthy male control subjects (C) and 9 male patients with uncomplicated type 1 diabetes mellitus (DM), as obtained before the inclusion in the study (see METHODS); SAP, systolic arterial pressure; DAP, diastolic arterial pressure; PRA, plasma renin activity; UAE, urinary albumin excretion rate; UNaV, sodium excretion rate; UNOxV, urinary excretion of NO2 ϩ NO3. *P Ͻ 0.005 for DM vs. C; and †P Ͻ 0.001 for DM vs. C. DM group, after administration of only regular insulin in the previous 24 h, an intravenous regular insulin pump infusion (Perfusion Secura, Braun, Germany) was initiated and then the infusion rate was titrated for the next 2 h to maintain a blood glucose (BG) between 4.5-5.5 mmol/l. Insulin infusion was continued for the remainder of the experiment at the same rate, averaging 0.22 Ϯ 0.05 mU·kg Ϫ1 ·min
Ϫ1
(0.13-0.28; Ref. 36) . After 2 h, with subjects on the seated position, after priming-dose injection, constant-rate infusion was initiated of 20% paraaminohippurate (PAH) and 10% inulin (INU) solutions (J. Monico, Venice, Italy) to maintain steady plasma levels of ϳ15 and 200 mg/l, respectively, also 300 ml of tap water were administered hourly. After a 1-h infusion and subjects voiding, a 45-min baseline clearance period was performed. At the end, after subjects voided again, a pump infusion of 3.0 g·kg Ϫ1 ·min Ϫ1 L-NAME (10 mg ampoules, Clinalfa, Switzerland) was initiated, followed by two 45-min clearance periods (L-NAMEP1 and L-NAMEP2, respectively; Refs. 33, 34, 38) . At the end of each 45-min period, subjects voided and samples of urine for Na ϩ and Li ϩ were taken, while UNOxV, cyclic guanosin-monophosphate (UcGMPV), and 8-isoprostane (U8-iso-PGF 2␣V), the latter used as an in vivo index of oxidative stress (15, 36, 37) , were measured at baseline and in the urine volume from the entire L-NAME infusion. Heparinized blood samples were drawn for INU and PAH every 15 min; BG, insulin, and Li ϩ every 45 min; and PRA and Na ϩ at the end of the baseline and L-NAMEP2 periods. SAP, DAP, and heart rate (HR) were measured every 5 min using an automated, oscillometric device (TM 2421; A&D, Tokio, Japan).
Calculations. Mean arterial pressure (MAP) was calculated as:
. Steady-state plasma levels of PAH and INU were maintained throughout the infusion, with a variability in the baseline period (1.8% PAH and 2.5% INU) close to that in duplicate analysis of single plasma samples (1.5 and 2.0%, respectively). PAH clearance and INU clearance (GFR) were, therefore, determined without bladder catheterization using a constant-infusion technique (33) (34) (35) (36) 38) . Four PAH clearance and GFR values in the baseline period and three in each L-NAME period were measured by dividing the PAH and INU infusion rates (based on the measured PAH and INU concentrations in infused solution and the infused volume per min) for each plasma PAH and INU concentration, using mean values in each period to express data. Based on the fixed renal PAH extraction at low plasma levels, no correction was made for PAH clearance, which was therefore considered equal to the "effective" renal plasma flow (ERPF), as we and others have previously reported (2, 13, 20, 32-36, 38, 42) . FF, RBF, and RVR were then calculated as GFR/ERPF, ERPF/(1 Ϫ fractional hematocrit), and MAP/RBF, respectively. Based on urinary Li ϩ and Na ϩ clearances (CLi and CNa) and GFR, Li ϩ and Na ϩ fractional excretion rates (FELi ϭ CLi/GFR and FENa ϭ CNa/GFR), and estimated "proximal" (or before MD) fractional reabsorption rate [FPR ϭ (GFR Ϫ CLi)/GFR] were also calculated (9, (33) (34) (35) (36) 38) .
Analytical methods. Standard methods were used for routine clinical and biochemical measurements. The methods for Li ϩ , Na ϩ , UUN, PAH, INU, PRA, insulin, C-peptide, UNOxV, UcGMPV, UAE, and U8-iso-PGF2␣V were previously described (33) (34) (35) (36) 38) .
Statistics. Data were expressed as the means Ϯ SE. Baseline values were compared in C vs. DM with unpaired Student t-test. Paired t-test was used for within-group differences at baseline between various infusions, for changes in variables from baseline to the end of L-NAME infusion, and for those in urine parameters from baseline to entire urine collection during L-NAME. Because of a nonnormal distribution (Kolmogoroff-Smirnoff test), Mann-Whitney U and Wilcoxon signed-rank tests were used for U8-iso-PGF2␣V. For BG, plasma Li ϩ and insulin, MAP, GFR, ERPF, RBF, RVR, and Li ϩ and Na ϩ urinary excretion during L-NAME, ANOVA, followed by Bonferroni's test for multiple comparisons, was performed, using SPSS 20.0 software package (IBM, Armonk, NY). In the ANOVA, a "split-plot," factorial design was used to compare data within each type of treatment, while a randomized block analysis was performed within each group of subjects. Factors considered as exerting an interaction in the analysis of data were time, type of treatment (PL vs. LOS), and type of subjects (C vs. DM). Two-tailed P Յ 0.05 were considered to indicate statistical significance.
RESULTS
Baseline characteristics. Baseline fasting BG, HbA1c, UN-O x V, and UAE were higher in DM patients vs. C, while PRA was lower (39) ( Table 1) .
Metabolic and hormonal effects of L-NAME infusion. Plasma Li ϩ declined significantly during each L-NAME infusion (P Ͻ 0.001) without between-group differences ( Table 2) . During PL ϩ L-NAME in healthy C volunteers (PL ϩ L-NAME-C), BG, plasma Na ϩ , and insulin did not change (P Ͼ 0.05); U8-iso-PGF2␣V rose; and PRA, UNO x V, and UcGMPV decreased (P Ͻ 0.005 for all) (5-7, 10, 13, 31, 33-35, 38, 42) .
During PL ϩ L-NAME-DM, because of constant-rate insulin infusion, plasma insulin was approximately two times higher than in PL ϩ L-NAME-C. BG remained unchanged (P Ͼ 0.05 vs. time) without exceeding 5.6 mmol/l close to clamped euglycemia (11) (12) (13) 32) . While baseline PRA was lower in PL ϩ L-NAME-DM vs. PL ϩ L-NAME-C (P Ͻ 0.005), PRA fell similarly in the two groups (P Ͼ 0.05). UNO x V, elevated at the baseline in the DM group (P Ͻ 0.005) and declined (P Ͻ 0.005) to a similar extent in the two groups (P Ͼ 0.05), while U8-iso-PGF2␣V, also higher at baseline in DM (P Ͻ 0.005), increased to a four times greater extent compared with PL ϩ L-NAME-C (P Ͻ 0.01). UcGMPV, similar at baseline vs. C, declined significantly (P Ͻ 0.005) and to the same extent as in PL ϩ L-NAME-C (P Ͼ 0.05).
At the baseline of the LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM infusion studies, PRA exhibited expected increases vs. the PL baseline (P Ͻ 0.001). During LOS ϩ L-NAME-C, the same changes as those during PL ϩ L-NAME-C were observed (P Ͼ 0.05), including the decline in PRA (P Ͻ 0.005). During LOS ϩ L-NAME-DM, PRA, UN-O x V, and UcGMPV fell as during LOS ϩ L-NAME-C (P Ͼ 0.05), while U8-iso-PGF2␣V still rose (P Ͻ 0.005), but such a change was lesser than that following PL ϩ L-NAME-DM (P Ͻ 0.005) and similar to those following both PL ϩ L-NAME-C and LOS ϩ L-NAME-C (P Ͼ 0.05).
BP and renal hemodynamic responses to L-NAME. At the baseline of PL ϩ L-NAME-C and PL ϩ L-NAME-DM, BP was similar between groups (P Ͼ 0.05), while GFR (Fig. 1) , RBF (Fig. 2) , and FF were higher and RVR lower in PL ϩ L-NAME-DM (all P Ͻ 0.005 vs. PL ϩ L-NAME-C; Table 3 ).
During PL ϩ L-NAME-C and PL ϩ L-NAME-DM, HR decreased (P Ͻ 0.01), while BP, still unchanged in the L-NAME P1 time period (P Ͼ 0.05 vs. baseline), increased later in L-NAME P2 (P Ͻ 0.01 vs. time). During PL ϩ L-NAME-C, GFR (Ϫ10%; Fig. 1 ), ERPF (Ϫ19%) and RBF (Ϫ19%; Fig. 2 ) decreased substantially and FF (ϩ10%) and RVR (ϩ32%) increased (P Ͻ 0.001 vs. time), with changes already significant during L-NAMEP1 (P Ͻ 0.01 vs. baseline; see Figs. 1 and 2) and without an increase in MAP.
During PL ϩ L-NAME-DM, the highly significant (P Ͻ 0.001 vs. time) renal hemodynamic changes were accentuated vs. PL ϩ L-NAME-C (Ϫ19% GFR, Ϫ31% ERPF and RBF, ϩ18% FF, and ϩ58% RVR, ANOVA interaction by type of subjects; P Ͻ 0.005), with variations from baseline already greater in DM during L-NAMEP1 (P Ͻ 0.05; Figs. 1 and 2) .
At the baseline of LOS ϩ L-NAME-C, BP and renal hemodynamic function were unchanged vs. the baseline PL ϩ L-NAME-C values (P Ͼ 0.05). In contrast, at the baseline of the LOS ϩ L-NAME-DM studies, ERPF and RBF (Fig. 2) were higher vs. the PL ϩ L-NAME-DM baseline (ϩ6.6%), while FF (Ϫ8.7%), RVR (Ϫ8.4%), and GFR (Ϫ3.0%; Fig. 1 ) were lower (P Ͻ 0.05).
During both LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM infusions, BP did not change from baseline (P Ͼ 0.05). During LOS ϩ L-NAME-C, GFR (Ϫ10%, Fig. 1 ), ERPF (Ϫ17%), and RBF (Ϫ17%; Fig. 2 ) decreased and FF (ϩ9%) and RVR (ϩ22%) increased to the same extent as in PL ϩ L-NAME-C (interaction by type of treatment: P Ͼ 0.05). In contrast, during LOS ϩ L-NAME-DM, renal hemodynamic changes, although still highly significant vs. time (P Ͻ 0.001), were blunted substantially vs. PL ϩ L-NAME-DM (Ϫ9 vs. Ϫ19% GFR, Ϫ20 vs. Ϫ31% ERPF and RBF, ϩ9 vs. ϩ18% FF, and ϩ27 vs. ϩ58% RVR, interaction by type of treatment: P Ͻ 0.005) and similar to those observed in the C group during both the PL ϩ L-NAME-C and LOS ϩ L-NAME-C infusion studies (P Ͼ 0.05).
To summarize, systemic L-NAME infusion lowered GFR (Fig. 1) , ERPF, and RBF ( Fig. 2) and increased RVR and FF. These BP-independent effects were not influenced by LOS in the C group. In contrast, responses to L-NAME in DM patients were enhanced vs. C during the PL phase of the study, and AT 1 blockade prevented these between-group differences.
Urinary Na ϩ and Li ϩ excretion responses to L-NAME. At the baseline of PL ϩ L-NAME-DM and PL ϩ L-NAME-C, UNaV (Fig. 3) , and CLi were similar (P Ͼ 0.05), with still lower FENa and higher FPR in DM vs. C (P Ͻ 0.02; Table 4 ).
During PL ϩ L-NAME-C, UNaV (Ϫ48%, Fig. 3 ), FENa (Ϫ41%), CLi (Ϫ33%), and FELi (Ϫ25%) declined and FPR rose (ϩ9%) (P Ͻ 0.001 vs. time), with variations already significant during L-NAMEP1 (P Ͻ 0.01 vs. baseline, Fig. 3 ). During PL ϩ L-NAME-DM, these variations were exaggerated [interaction by type of subjects vs. PL ϩ L-NAME-C: P Ͻ 0.001 for UNaV (Ϫ74%, Fig. 3 ), CLi (Ϫ60%), and FELi (Ϫ50% ); P Ͻ 0.005 for FPR (ϩ14%); P Ͻ 0.05 for FENa Values are means Ϯ SE. Plasma and urinary biochemical and hormonal parameters in 14 control individuals (C) and 9 diabetic patients (DM) during 2 infusion studies, each divided in 2, consecutive 45-min periods (L-NAMEP1 and L-NAMEP2) of 3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 N G -nitro-L-arginine-methyl-ester (L-NAME), preceded by 3-day treatment with either placebo (PL ϩ L-NAME-C and PL ϩ L-NAME-DM) or 50 mg losartan (LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM). BG, blood glucose; UUN, urinary urea nitrogen; UcGMPV, urinary excretion rate of cyclic guanosin-monophosphate; U8-iso-PGF2␣V, urinary excretion rate of 8-isoprostane (U8-iso-PGF2␣). *P Ͻ 0.005 for DM vs. C at baseline; †P Ͻ 0.001, ANOVA for time-dependent changes; ‡P Ͻ 0.001 vs. baseline C-PL and DM-PL, respectively; §P Ͻ 0.005, end L-NAME vs. baseline or L-NAME-P1 ϩ P2 vs. baseline; P Ͻ 0.001 L-NAME-P1ϩ P2 vs. baseline; ¶P Ͻ 0.01 for changes from baseline during PL ϩ L-NAME-DM vs. PL ϩ L-NAME-C, LOS ϩ L-NAME-C, and LOS ϩ L-NAME-DM.
(Ϫ68%)], with changes from baseline already greater in DM during L-NAMEP1 (P Ͻ 0.05; Fig. 3) .
At the baseline of LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM, UNaV (Fig. 3) , CLi, FENa, FELi, and FPR were similar within each group compared with the PL baseline (P Ͼ 0.05), and between-group differences still remained significant (P Ͻ 0.02). During LOS ϩ NAME-C, the alterations in Na ϩ (Fig. 3 ) and Li ϩ handling were essentially the same as during PL ϩ L-NAME-C (interaction for type of treatment: P Ͼ 0.05). In contrast, during LOS ϩ L-NAME-DM, the changes in UNaV (Ϫ51%), FENa (Ϫ48%), CLi (Ϫ39%), FELi (Ϫ23%), and FPR (ϩ9%; P Ͻ 0.001 vs. time) were significantly blunted vs. PL ϩ L-NAME-DM (interaction by type of treatment: P Ͻ 0.02, except P Ͻ 0.001 for FELi) and similar to those following PL ϩ L-NAME-C and LOS ϩ L-NAME-C (P Ͼ 0.05).
To summarize, Na ϩ and Li ϩ excretion was reduced during L-NAME, with enhanced Li ϩ -derived FPR. These changes, not affected by LOS in C, were exaggerated in DM after PL and blunted after AT 1 blockade, thereby abolishing between-group differences.
DISCUSSION
In this study, participants underwent a low-dose, systemic L-NAME infusion to inhibit NOS. While 0.5-1 g·kg Ϫ1 ·min
Ϫ1
L-NAME infusion does not affect BP or renal hemodynamic function in humans (10, 35) , decreases in RBF, GFR, and UNaV occur within 30 -45 min of administering 3-5 g· kg Ϫ1 ·min Ϫ1 L-NAME (10, 33, 34, 38) . These doses of L-NAME cause 5-7% increases in MAP that are seen only after renal function changes have already occurred, which may reflect counterregulatory baroreflex activity against the BP effect of withdrawing systemic NO bioactivity (10, 33, 34, 38, 47) . In contrast, almost immediate increases in BP develop with either high-dose L-NAME or standard 1-4 mg/kg L-NMMA infusions, along with simultaneous renal hemodynamic changes, reaching BP levels that often exceed ϩ10% above baseline (5, 6, 10, 16, 21, 28, 42,  46) . Thus the systemic effects of high-dose L-NAME or L-NMMA likely influence kidney function, as also suggested by the exaggerated reductions in RBF and GFR and increases in FF shown in animals and humans with acute NOSI-induced BP increases, and may even cause a pressure natriuresis (3, 4, 21) . We therefore used a 3 g·kg Ϫ1 ·min Ϫ1 L-NAME infusion in an effort to limit the renal effects of the concomitant changes in renal perfusion pressure, thereby reproducing, as much as possible in humans, a selective intrarenal NOSI (1, 19).
Our first major observation was that renal hemodynamic responses to L-NAME were accentuated in DM patients vs. C, consistent with early experimental data (24) and our previous work involving L-NMMA-infused hyperfiltering DM patients (13) . LOS+L-NAME-C LOS+L-NAME-DM L-NAME L-NAME L-NAME L-NAME p<0.005 VS PL+L-NAME-C, Interaction by type of subjects p> 0.05 VS PL+L-NAME-C, Interaction by type of treatment p> 0.005 VS PL+L-NAME-DM Interaction by type of treatment p > 0.05 VS LOS+L-NAME-C by type of subjects
. Renal blood flow (RBF) in control individuals (C) and diabetic patients (DM) at baseline (B) and during 2 infusion periods of L-NAME (L-NAMEP1
and L-NAMEP2) and preceded by 3-day treatment with either placebo (PL ϩ L-NAME-C and PL ϩ L-NAME-DM) or Losartan (LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM; means Ϯ SE). ‡P Ͻ 0.005, for higher RBF in the DM group vs. C at the PL baseline. *P Ͻ 0.05, for higher RBF in the DM group at LOS baseline vs. the PL baseline. §P Ͻ 0.01, for decreases in RBF vs. baseline during L-NAMEP1 (⌬RBF). ¶P Ͻ 0.05, for greater ⌬RBF in PL ϩ L-NAME-DM vs. PL ϩ L-NAME-C (Ϫ142 Ϯ 15 vs. Ϫ103 Ϯ 18 ml·min Ϫ1 ·1.73 m Ϫ2 ). #P Ͻ 0.01, for smaller ⌬RBF in LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM (Ϫ76 Ϯ 25 and Ϫ81 Ϯ 22 ml·min Ϫ1 ·1.73 m Ϫ2 , respectively) vs. PL ϩ L-NAME-DM, without differences vs. PL ϩ L-NAME-C (P Ͼ 0.05). P Ͻ 0.001, for changes in RBF during the whole time-course of each infusion. Bottom insets: report the ANOVA P values for interactions exerted on the L-NAME-induced changes in RBF by type of subjects, C or DM, after PL (greater during PL ϩ L-NAME-DM vs. PL ϩ L-NAME-C, P Ͻ 0.005); by type of treatment, PL or LOS, in the DM group (blunted during LOS ϩ L-NAME-DM vs. PL ϩ L-NAME-DM, P Ͻ 0.005); and by type of subjects, C or DM, after LOS (similar during LOS ϩ L-NAME-DM and LOS ϩ L-NAME-C, P Ͼ 0.05). LOS+L-NAME-C LOS+L-NAME-DM L-NAME L-NAME L-NAME L-NAME p< 0.005 VS PL+L-NAME-C, Interaction by type of subjects p> 0.05 VS PL+L-NAME-C, Interaction by type of treatment p> 0.005 VS PL+L-NAME-DM Interaction by type of treatment p > 0.05 VS LOS+L-NAME-C by type of subjects 
and L-NAMEP2) and preceded by 3-day treatment with either placebo (PL ϩ L-NAME-C and PL ϩ L-NAME-DM) or Losartan (LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM; means Ϯ SE). ‡P Ͻ 0.005, for higher GFR in the DM group vs. C at the PL baseline. *P Ͻ 0.05, for higher GFR in the DM group at LOS baseline vs. PL baseline. §P Ͻ 0.01, for decreases in GFR vs. baseline during L-NAMEP1 (⌬GFR). ¶P Ͻ 0.05, for greater ⌬GFR in PL ϩ L-NAME-DM vs. PL ϩ L-NAME-C at L-NAMEP1 (Ϫ9.8 Ϯ 2.5 vs. Ϫ6.2 Ϯ 1.8 ml·min , respectively) vs. PL ϩ L-NAME-DM, without differences vs. PL ϩ L-NAME-C (P Ͼ 0.05). P Ͻ 0.001, for decreases in GFR in the whole time-course of each infusion vs. time. Bottom insets: report the ANOVA P values for interactions exerted on the L-NAMEinduced changes in GFR by type of subjects, C or DM, after PL (greater during PL ϩ L-NAME-DM vs. PL ϩ L-NAME-C, P Ͻ 0.005); by type of treatment, PL or LOS, in the DM group (blunted during LOS ϩ L-NAME-DM vs. PL ϩ L-NAME-DM, P Ͻ 0.005); and by type of subjects, C or DM, after LOS (similar during LOS ϩ L-NAME-DM and LOS ϩ L-NAME-C, P Ͼ 0.05).
The changes in renal hemodynamic function were already more pronounced in DM vs. C during L-NAMEP1, without concomitant increases in BP, which indicates a normal ability of baroreflex mechanisms to offset any early BP effect of low-dose L-NAME in DM patients (10, 33, 34, 38, 47) . Notably, the BP increases during L-NAMEP2 in DM (ϩ 8% MAP) were the same as in the C group and lower compared with those previously observed in hyperfiltering DM patients following L-NMMA (ϩ18%) (13) . Therefore, the accentuated renal effects of L-NAME in DM were independent of potentially greater increases in renal perfusion pressure.
Based on the baseline higher values for UNO x V, GFR, and RBF and lower for RVR, the exaggerated renal effects of L-NAME in the DM group could be attributed to the withdrawal of higher baseline NO bioactivity (7, 12, 14, 30, 31, 43) . However, instead of the expected greater fall in UNO x V in DM, similar between-group reductions in UNO x V followed L-NAME, consistent with similar net effects on NO production. Changes in UNO x V may not, however, reflect renal NO bioactivity, especially when NOSI is superimposed on elevated levels of oxidative stress, as indicated by the higher baseline U8-iso-PGF2␣V in the DM group (15, 36, 44) .
In C group, L-NAME did result in the expected increase in U8-iso-PGF2␣V, reflecting the withdrawal of "buffering" activity against the formation of reactive oxygen species (ROS), such as superoxide anion (O 2 Ϫ ; Refs. 8, 25, 30, 31) . This effect was, however, four times greater in DM group vs. C, suggesting that NOSI resulted in exaggerated ROS production, which, in turn, may have enhanced dissipation of NO toward the formation of peroxynitrite (8, 25, 30, 31) . Therefore, NOSIinduced reductions in intrarenal NO bioavailability may still have been much greater in DM vs. C, despite similar variations in UNO x V.
Increased ROS formation therefore participates in the renal changes to NOSI and ANG II, which, in turn, may also affect renal function through an AT 1 -dependent increased O 2 Ϫ generation (8, 30, 31) . As a result, upregulation of the intrarenal RAS may also have contributed in DM individuals to exaggerated effects of L-NAME on both ROS formation and renal hemodynamic function. Taken together, the results of the PL ϩ Table 3 . Blood pressure and renal hemodynamic function Values are means Ϯ SE. Blood pressure and renal hemodynamic function in 14 control individuals (C) and 9 diabetic patients (DM) during two infusion studies, each divided in 2, consecutive 45-min periods (L-NAMEP1 and L-NAMEP2) of 3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 L-NAME, preceded by a 3-day treatment with either placebo (PL ϩ L-NAME-C and PL ϩ L-NAME-DM) or 50 mg losartan (LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM). MAP, mean arterial pressure; HR, heart rate; GFR, glomerular filtration rate; FF, filtration fraction; ERPF, effective renal plasma flow; RBF, renal blood flow; RVR, renal vascular resistances. *P Ͻ 0.01, ANOVA time-dependent changes; †P Ͻ 0.005, PL ϩ L-NAME-DM vs. PL ϩ L-NAME-C or LOSϩL-NAME-DM vs. C-LOS at baseline; ‡P Ͻ 0.05, LOS ϩ L-NAME-DM vs. PL ϩ L-NAME-DM at baseline; §P Ͻ 0.01, L-NAME P1 vs. baseline; P Ͻ 0.001, ANOVA for time-dependent changes; ¶P Ͻ 0.005, ANOVA comparison of time-dependent changes during PL ϩ L-NAME-DM vs. PL ϩ L-NAME-C (interaction by type of subjects) and during LOS ϩ L-NAME-DM vs. PL ϩ L-NAME-DM (interaction by type of treatment).
L-NAME infusions indicate that increased NO synthesis in DM does not completely explain between-group differences in renal responses to L-NAME. Instead, other mechanisms, such as the exaggerated ROS formation, upregulated intrarenal RAS, or both, likely lead in DM to an increased sensitivity of renal hemodynamic function to NOSI.
In keeping with intrarenal RAS activation, LOS modestly increased baseline RBF and decreased RVR, GFR, and FF in the DM group only (11, 12, 23, 27, 39, 43) . In contrast, in the C group neither baseline renal hemodynamic function nor its changes during L-NAME were influenced by AT 1 blockade vs. PL, consistent with previous data from healthy individuals and non-DM patients (6, 16, 33, 38, 46) demonstrating that, under conditions of suppressed or even moderately activated intrarenal RAS activity, NO-ANG II interactions likely do not play an important role in the control of renal hemodynamic function.
As the second major finding, the responses to L-NAME were blunted by LOS vs. PL in the DM group only, indicating that, in contrast to the C group, NO-RAS interactions become critical in the control of renal hemodynamic function in Na ϩ -replete, uncomplicated type 1 DM patients. In addition, renal hemodynamic responses were similar in DM vs. C after LOS, suggesting that AT 1 blockade prevented the accentuated baseline effects of L-NAME in DM. This observation is consistent with the hypothesis that the main cause of between-group different responses during the PL phase of the study was the endogenously upregulated RAS in DM left unopposed by NOSI, rather than the withdrawal of NO by itself.
From a mechanistic perspective, since AT 1 blockade did not affect baseline UNO x V or U8-iso-PGF2␣V in either group, it is unlikely that between-group differences in renal hemodynamic responses to L-NAME after LOS reflected differential effects of AT 1 blockade on baseline NO or ROS production. However, marked between-group differences emerged when the responses to L-NAME after LOS vs. PL were compared between DM and C. In the C group, LOS did not affect the increase in U8-iso-PGF2␣V during L-NAME, consistent with the minimal role of intrarenal ANG II in salt-replete healthy humans (6, 16, 33, 38) . In contrast, LOS blunted the exaggerated effect on U8-iso-PGF2␣V observed during PL ϩ L-NAME in the DM group, thereby reducing any potential influence of increased ROS production on the renal hemodynamic effects of NOSI. The upregulated intrarenal RAS may therefore have induced greater renal hemodynamic function sensitivity to NOSI in DM also through exaggerated effects on AT 1 -mediated ROS formation (30) .
Under baseline conditions, the DM group exhibited higher GFR values and lower values for FENa and FELi, with higher Li ϩ -derived FPR, consistent with elevated tubular reabsorption rate (12, 13, 20, 36) . During the PL phase of the study, L-NAME further reduced FENa and FELi and increased FPR, and this effect was enhanced in DM vs. C. The lowered Na ϩ and Li ϩ filtered load and variations in peritubular "physical forces" secondary to the L-NAME-induced renal hemodynamic changes would have contributed to the increased reabsorption. However, these findings are likely to primarily reflect a further increase in tubular reabsorptive transport rate, mainly located in the proximal tubule. Therefore, although NO also affects reabsorption in tubular sites distal to the MD (22) , NOSI likely causes an increase in proximal tubular transport, which is exaggerated based on diabetic status. In contrast to the PL studies, no between-group differences in tubular function were seen after LOS. Since AT 1 blockade prevented the exaggerated increase in reabsorption during L-NAME in DM without influencing such responses in C, NO-RAS interactions likely contribute substantially to the augmented effects of L-NAME on proximal tubular reabsorption in DM.
From a clinical perspective, although RAS blockade only partially reduces renal hemodynamic dysfunction and the development of nephropathy in type 1 DM (43), the angiotensin-converting enzyme-inhibitor or AT 1 -blocker-based regimens remain the accepted key therapies in this area. In this set of experiments, AT 1 blockade blunted the betweengroup differences to NOSI, including the exaggerated ROS production in DM, emphasizing the potential impact of NO-RAS interactions on OS. While caution should be taken in generalizing results of acute NOSI studies in uncomplicated type 1 DM patients to more advanced stages of nephropathy, our results may have some implications for later stages of the disease. Since renal NO bioavailability declines over time in humans with DM (25, 45) , ROS production may accelerate due to the unopposed action of the activated intrarenal RAS. Due to its beneficial effect on the renal NO-RAS interactions, RAS blockade may therefore help to slow progression of DM nephropathy in part through the limitation of elevated renal ROS production. Fig. 3 . Sodium excretion rate (UNaV) in control individuals (C) and diabetic patients (DM) at baseline (B) and during 2 infusion periods of L-NAME (L-NAMEP1 and L-NAMEP2) and preceded by 3-day treatment with either placebo (PL ϩ L-NAME-C and PL ϩ L-NAME-DM) or Losartan (LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM; means Ϯ SE). §P Ͻ 0.01, for decreases in UNaV vs. baseline during L-NAMEP1 (⌬UNaV). ¶P Ͻ 0.05, for greater ⌬UNaV in PL ϩ L-NAME-DM vs. PL ϩ L-NAME-C (Ϫ73 Ϯ 10 vs. Ϫ51 Ϯ 8 mol/min). #P Ͻ 0.05, for smaller ⌬UNaV in LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM (Ϫ47 Ϯ 9 mol/min and Ϫ44 Ϯ 10, respectively) vs. PL ϩ L-NAME-DM, without differences vs. PL ϩ L-NAME-C (P Ͼ 0.05). P Ͻ 0.001, for decreases in UNaV in the whole time course of each infusion. Bottom insets: report the ANOVA P values for interactions exerted on the L-NAME-induced changes in UNaV by type of subjects, C or DM, after PL (greater during PL ϩ L-NAME-DM vs. PL ϩ L-NAME-C, P Ͻ 0.005); by type of treatment, PL or LOS, in the DM group (blunted during LOS ϩ L-NAME-DM vs. PL ϩ L-NAME-DM, P Ͻ 0.005); and by type of subjects, C or DM, after LOS (similar during LOS ϩ L-NAME-DM and LOS ϩ L-NAME-C, P Ͼ 0.05).
Our study has some limitations. First, we cannot exclude the possibility that renal PAH extraction was modified by L-NAME or LOS, thus affecting PAH-derived estimates of ERPF and RBF. These theoretical interactions cannot, unfortunately, be determined in human studies. Based on extensive previous work using these techniques in humans, and because of supratherapeutic doses of drugs required to change PAH transport in in vitro studies (17) , the effect of these potential confounders is likely to have been minimal. Also, since the sample size was small, which may have limited our ability to detect some between-group differences, we attempted to minimize such an effect by careful prestudy dietary preparation, including a monitoring of Na ϩ , proteins, antioxidants, and NOx intake. In addition, our study groups were homogeneous in age and BMI and included male participants only, which ruled out any gender-related differences in the renal hemodynamic function (11, 12) . We also decreased variability by using a study design that allowed each subject to act as his own control. Furthermore, because 7% of the filtered Li ϩ may be reabsorbed distally to the MD (9), some caution should be taken in interpreting data of Li ϩ -derived FPR. However, while Na repletion and water loading would have minimized the "distal" Li ϩ reabsorption (9, 36), L-NAME resulted in reductions in FELi of 25% in C and 50% in DM. Finally, as insulin and hyperglycemia may influence renal hemodynamic function and intrarenal RAS in DM individuals (11, 12, 32) , we controlled for these variables through an insulin infusion, resulting in similar insulin and BG levels in DM irrespective of the PL or LOS pretreatment. It was therefore unlikely that these factors played an important role in our study.
Conclusions.
The renal hemodynamic and excretory effects of NOSI with low-dose L-NAME infusion are exaggerated in uncomplicated type 1 DM patients vs. healthy individuals, consistent with a state of baseline NO upregulation in DM. However, short-term LOS, without effects in non-DM controls, prevents the accentuated renal vasoconstriction and Na ϩ retention to L-NAME in DM. Therefore, the hemodynamic and tubular actions of the endogenously upregulated RAS, left unopposed by the acutely reduced NO, critically contribute to the exaggerated responses to L-NAME in DM. This strongly suggests an augmented role of NO-RAS interactions in the renal hemodynamic and excretory function in DM, which may effectively be counteracted by AT1-blockade. Values are means Ϯ SE. Time-course of Na ϩ and Li ϩ excretion and Li ϩ -derived, estimated fractional proximal reabsorption in 14 control individuals (C) and 9 diabetic patients (DM) during 2 infusion studies, each divided in 2, consecutive 45-min periods (L-NAME P1 and L-NAME P2) of 3 g ⅐ kg Ϫ1 ⅐ min Ϫ1 L-NAME, preceded by 3-day treatment with either placebo (PL ϩ L-NAME-C and PL ϩ L-NAME-DM) or 50 mg Losartan (LOS ϩ L-NAME-C and LOS ϩ L-NAME-DM). UNaV, absolute Na ϩ excretion rate; FENa, fractional Na ϩ excretion rate; CLi, Li ϩ urinary clearance; FELi, fractional Li ϩ excretion rate; FPR, Li ϩ -derived, estimated fractional proximal reabsorption; *P Ͻ 0.01, L-NAME P1 vs. baseline; †P Ͻ 0.001, ANOVA for time-dependent changes; ‡P Ͻ 0.02, DM vs. C at baseline; §P Ͻ 0.001, P Ͻ 0.05, ¶P Ͻ 0.005, ANOVA comparison of time-dependent changes during P ϩ L-NAME-DM vs. PL ϩ L-NAME-C, interaction by type of subjects; #P Ͻ 0.02, ϱP Ͻ 0.001, ANOVA comparison of time-dependent changes during LOS ϩ L-NAME-DM vs. PL ϩ L-NAME-DM, interaction by type of treatment. 
